SCHEMBL3777248

SCHEMBL3777248

Cc1nc2cc(Cl)cc(O)c2c(C)c1Cc1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.41
KMT2A Q03164 3/20 0.40
PLA2G2A P14555 1/20 0.40
ENPP2 Q13822 1/20 0.39
ENPP1 P22413 1/20 0.38
MAPT P10636 4/20 0.37
MEN1 O00255 2/20 0.37
NPSR1 Q6W5P4 1/20 0.36
HSP90AB1 P08238 1/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 5/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ERCC1 P07992 1/20 0.34
ERCC4 Q92889 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788414 0.91 RORC (0.41) RORCKMT2APLA2G2AENPP2ENPP1
SCHEMBL3781462 0.83 PLA2G2A (0.42) RORCKMT2APLA2G2AENPP2ENPP1
SCHEMBL3777107 0.80 KDM4E (0.46) RORCPLA2G2AENPP2MAPTNPSR1
SCHEMBL3782672 0.80 KMT2A (0.36) RORCKMT2AENPP2MAPTMEN1
SCHEMBL27826433 0.79 PLA2G2A (0.43) RORCKMT2APLA2G2AENPP2MAPT
SCHEMBL27722687 0.78 PLA2G2A (0.41) RORCKMT2APLA2G2AENPP2MAPT
SCHEMBL3777623 0.78 PLA2G2A (0.46) PLA2G2ANPSR1LMNASMN1; SMN2L3MBTL1
SCHEMBL3775557 0.76 KMT2A (0.40) RORCKMT2AENPP2ENPP1MAPT
SCHEMBL3780495 0.74 PTGDR2 (0.48) RORCKMT2APLA2G2AENPP2NPSR1
SCHEMBL3781581 0.74 PLA2G2A (0.38) RORCKMT2APLA2G2AENPP2ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 RORC 30/4885KMT2A 3406/4885PLA2G2A 1779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.